Amgen Inc. which can be found using ticker (AMGN) now have 24 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The target price High/Low ranges between $405.00 and $200.00 calculating the mean target price we have $332.30. Given that the stocks previous close was at $317.48 and the analysts are correct then there would likely be a percentage uptick in value of 4.7%. The 50 day MA is $327.59 and the 200 day MA is $303.95. The company has a market capitalization of 171.93B. The current share price for the company is: $319.97 USD
The potential market cap would be $179,954,846,055 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 55.07, revenue per share of $57.66 and a 4.48% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
